Using protein homology models for structure-based studies: Approaches to model refinement

TheScientificWorldJournal

Volumn 6, Issue , 2006, Pages 1542-1554

  Kairys, V ^a   Gilson, M K ^b   Fernandes, M X ^a  

^a Centro de Quimica da Madeira   (Portugal)

^b UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE   (United States)

Author keywords

Docking; Drug design; Homology modeling; Molecular dynamics

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; HISTONE DEACETYLASE;

BINDING SITE; DRUG DESIGN; ENZYME BINDING; LIGAND BINDING; MOLECULAR DYNAMICS; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SHORT SURVEY; STRUCTURE ANALYSIS;

COMPUTATIONAL BIOLOGY; DRUG DESIGN; MODELS, CHEMICAL; STRUCTURAL HOMOLOGY, PROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845493051     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2006.250     Document Type: Short Survey

References (64)

1. Goldsmith-Fischman, S. and Honig, B. (2003) Structural genomics: computational methods for structure analysis. Protein Sci. 12, 1813-1821.
2. Fischer, D. (2006) Servers for protein structure prediction. Curr. Opin. Struct. Biol. 16, 178-182.
3. Ginalski, K. (2006) Comparative modeling for protein structure prediction. Curr. Opin. Struct. Biol. 16, 172-177.
4. Venclovas, Č. (2003) Comparative modeling in CASP5: progress is evident, but alignment errors remain a significant hindrance. Proteins 53(Suppl 6), 380-388.
5. Kryshtafovych, A., Venclovas, Č., Fidelis, K., and Moult, J. (2005) Progress over the first decade of CASP experiments. Proteins 61(Suppl 7), 225-236.
6. Halperin, I., Ma, B., Wolfson, H., and Nussinov, R. (2002) Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 47, 409-443.
7. Kitchen, D.B., Decornez, H., Furr, J.R., and Bajorath, J. (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov. 3, 935-949.
8. Mohan, V., Gibbs, A.C., Cummings, M.D., Jaeger, E.P., and DesJarlais, R.L. (2005) Docking: successes and challenges. Curr. Pharm. Des. 11, 323-333.
9. Abagyan, R. and Totrov, M. (2001) High-throughput docking for lead generation. Curr. Opin. Chem. Biol. 5, 375-382.
10. McGovern, S.L. and Shoichet, B.K. (2003) Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 46, 2895-2907.
11. Diller, D.J. and Li, R. (2003) Kinases, homology models, and high throughput docking. J. Med. Chem. 46, 4638-4647.
12. Oshiro, C., Bradley, E.K., Eksterowicz, J., Evensen, E., Lamb, M.L., Lanctot, J.K., Putta, S., Stanton, R., and Grootenhuis, P.D. (2004) Performance of 3D-database molecular docking studies into homology models. J. Med. Chem. 47, 764-767.
13. Schapira, M., Raaka, B.M., Das, S., Fan, L., Totrov, M., Zhou, Z., Wilson, S.R., Abagyan, R., and Samuels, H.H. (2003) Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc. Natl. Acad. Sci. U. S. A. 100, 7354-7359.
14. Kairys, V., Fernandes, M.X., and Gilson, M.K. (2006) Screening drug-like compounds by docking to homology models: a systematic study. J. Chem. Inf. Model. 46, 365-379.
15. Marhefka, C.A., Moore, B.M., 2nd, Bishop, T.C., Kirkovsky, L., Mukherjee, A., Dalton, J.T., and Miller, D.D. (2001) Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. J. Med. Chem. 44, 1729-1740.
16. Wang, D.F., Helquist, P., Wiech, N.L., and Wiest, O. (2005) Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 48, 6936-6947.
17. Chen, L., Gui, C., Luo, X., Yang, Q., Gunther, S., Scandella, E., Drosten, C., Bai, D., He, X., Ludewig, B., Chen, J., Luo, H., Yang, Y., Yang, Y., Zou, J., Thiel, V., Chen, K., Shen, J., Shen, X., and Jiang, H. (2005) Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. J. Virol. 79, 7095-7103.
18. Xiong, B., Gui, C.S., Xu, X.Y., Luo, C., Chen, J., Luo, H.B., Chen, L.L., Li, G.W., Sun, T., Yu, C.Y., Yue, L.D., Duan, W.H., Shen, J.K., Qin, L., Shi, T.L., Li, Y.X., Chen, K.X., Luo, X.M., Shen, X., Shen, J.H., and Jiang, H.L. (2003) A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin. 24, 497-504.
19. Miguet, L., Zhang, Z., Barbier, M., and Grigorov, M.G. (2006) Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors. J. Comput. Aided Mol. Des. 20, 67-81.
20. Wang, R., Lu, Y., and Wang, S. (2003) Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 46, 2287-2303.
21. Marsden, P.M., Puvanendrampillai, D., Mitchell, J.B., and Glen, R.C. (2004) Predicting protein-ligand binding affinities: a low scoring game? Org. Biomol. Chem. 2, 3267-3273.
22. Kemp, C.A., Flanagan, J.U., van Eldik, A.J., Marechal, J.D., Wolf, C.R., Roberts, G.C., Paine, M.J., and Sutcliffe, M.J. (2004) Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J. Med. Chem. 47, 5340-5346.
23. Arienti, K.L., Brunmark, A., Axe, F.U., McClure, K., Lee, A., Blevitt, J., Neff, D.K., Huang, L., Crawford, S., Pandit, C.R., Karlsson, L., and Breitenbucher, J.G. (2005) Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem. 48, 1873-1885.
24. Hillisch, A., Peters, O., Kosemund, D., Müller, G., Walter, A., Schneider, B., Reddersen, G., Elger, W., and Fritzemeier, K.H. (2004) Dissecting physiological roles of estrogen receptor a and β with potent selective ligands from structure-based design. Mol. Endocrinol. 18, 1599-1609.
25. Furet, P., Meyer, T., Mittl, P., and Fretz, H. (2001) Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching. J. Comput. Aided Mol. Des. 15, 489-495.
26. Warhurst, D.C. (2002) Resistance to antifolates in Plasmodium falciparum, the causative agent of tropical malaria. Sci. Prog. 85, 89-111.
27. Zhang, X., Shirahatti, N.V., Mahadevan, D., and Wright, S.H. (2005) A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2). J. Biol. Chem. 280, 34813-34822.
28. Sunaga, S., Yoshimori, A., Shiokawa, D., and Tanuma, S. (2006) Structure basis for the inhibitory mechanism of a novel DNase γ-specific inhibitor, DR396. Bioorg. Med. Chem. 14, 4217-4226.
29. Claussen, H., Buning, C., Rarey, M., and Lengauer, T. (2001) FlexE: efficient molecular docking considering protein structure variations. J. Mol. Biol. 308, 377-395.
30. Schafferhans, A. and Klebe, G. (2001) Docking ligands onto binding site representations derived from proteins built by homology modelling. J. Mol. Biol. 307, 407-427.
31. Pogozheva, I.D., Przydzial, M.J., and Mosberg, H.I. (2005) Homology modeling of opioid receptor-ligand complexes using experimental constraints. AAPS J. 7, E434-448.
32. van Dongen, M., Weigelt, J., Uppenberg, J., Schultz, J., and Wikström, M. (2002) Structure-based screening and design in drug discovery. Drug Discov. Today 7, 471-478.
33. Rockey, W.M. and Elcock, A.H. (2005) Rapid computational identification of the targets of protein kinase inhibitors. J. Med. Chem. 48, 4138-4152.
34. Bower, M.J., Cohen, F.E., and Dunbrack, R.L., Jr. (1997) Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J. Mol. Biol. 267, 1268-1282.
35. Lindahl, E., Hess, B., and van der Spoel, D. (2001) GROMACS 3.0: a package for molecular simulation and trajectory analysis. J. Mol. Mod. 7, 306-317.
36. Johnson, M.A., Höög, C., and Pinto, B.M. (2003) A novel modeling protocol for protein receptors guided by bound-ligand conformation. Biochemistry 42, 1842-1853.
37. Bissantz, C., Bernard, P., Hibert, M., and Rognan, D. (2003) Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 50, 5-25.
38. Bissantz, C., Logean, A., and Rognan, D. (2004) High-throughput modeling of human G-protein coupled receptors: amino acid sequence alignment, three-dimensional model building, and receptor library screening. J. Chem. Inf. Comput. Sci. 44, 1162-1176.
39. Ashton, M., Charlton, M.H., Schwarz, M.K., Thomas, R.J., and Whittaker, M. (2004) The selection and design of GPCR ligands: from concept to the clinic. Comb. Chem. High Throughput Screen. 7, 441-452.
40. Evers, A., Gohlke, H., and Klebe, G. (2003) Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J. Mol. Biol. 334, 327-345.
41. Evers, A. and Klebe, G. (2004) Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 47, 5381-5392.
42. Evers, A. and Klabunde, T. (2005) Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 48, 1088-1097.
43. Verdonk, M.L., Cole, J.C., Hartshorn, M.J., Murray, C.W., and Taylor, R.D. (2003) Improved protein-ligand docking using GOLD. Proteins 52, 609-623.
44. Muegge, I. and Martin, Y.C. (1999) A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 42, 791-804.
45. Evers, A., Hessler, G., Matter, H., and Klabunde, T. (2005) Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J. Med. Chem. 48, 5448-5465.
46. Takami, A., Iwakubo, M., Okada, Y., Kawata, T., Odai, H., Takahashi, N., Shindo, K., Kimura, K., Tagami, Y., Miyake, M., Fukushima, K., Inagaki, M., Amano, M., Kaibuchi, K., and Iijima, H. (2004) Design and synthesis of Rho kinase inhibitors (I). Bioorg. Med. Chem. 12, 2115-2137.
47. Gessner, G., Zacharias, M., Bechstedt, S., Schönherr, R., and Heinemann, S.H. (2004) Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol. Pharmacol. 65, 1120-1129.
48. von Langen, J., Fritzemeier, K.H., Diekmann, S., and Hillisch, A. (2005) Molecular basis of the interaction specificity between the human glucocorticoid receptor and its endogenous steroid ligand cortisol. Chembiochem 6, 1110-1118.
49. Massova, I. and Kollman, P.A. (2000) Combined molecular mechanical and continuum solvent approach (MMPBSA/GBSA) to predict ligand binding. Perspect. Drug Discov. Des. 18, 113-135.
50. Kramer, B., Rarey, M., and Lengauer, T. (1999) Evaluation of the FLEXX incremental construction algorithm for protein-ligand docking. Proteins 37, 228-241.
51. Zabell, A.P., Corden, S., Helquist, P., Stauffacher, C.V., and Wiest, O. (2004) Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase. Bioorg. Med. Chem. 12, 1867-1880.
52. Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., and Karplus, M. (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comp. Chem. 4, 187-217.
53. Waterman, M.R. and Lepesheva, G.I. (2005) Sterol 14α-demethylase, an abundant and essential mixed-function oxidase. Biochem. Biophys. Res. Commun. 338, 418-422.
54. Rupp, B., Raub, S., Marian, C., and Holtje, H.D. (2005) Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole. J. Comput. Aided Mol. Des. 19, 149-163.
55. Moran, O., Galietta, L.J., and Zegarra-Moran, O. (2005) Binding site of activators of the cystic fibrosis transmembrane conductance regulator in the nucleotide binding domains. Cell. Mol. Life Sci. 62, 446-460.
56. Bjelic, S. and Åqvist, J. (2004) Computational prediction of structure, substrate binding mode, mechanism, and rate for a malaria protease with a novel type of active site. Biochemistry 43, 14521-14528.
57. Desai, P.V., Patny, A., Sabnis, Y., Tekwani, B., Gut, J., Rosenthal, P., Srivastava, A., and Avery, M. (2004) Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 47, 6609-6615.
58. Sabnis, Y., Rosenthal, P.J., Desai, P., and Avery, M.A. (2002) Homology modeling of falcipain-2: validation, de novo ligand design and synthesis of novel inhibitors. J. Biomol. Struct. Dyn. 19, 765-774.
59. Sabnis, Y.A., Desai, P.V., Rosenthal, P.J., and Avery, M.A. (2003) Probing the structure of falcipain-3, a cysteine protease from Plasmodium falciparum: comparative protein modeling and docking studies. Protein Sci. 12, 501-509.
60. Muegge, I. and Enyedy, I.J. (2004) Virtual screening for kinase targets. Curr. Med. Chem. 11, 693-707.
61. Schapira, M., Abagyan, R., and Totrov, M. (2003) Nuclear hormone receptor targeted virtual screening. J. Med. Chem. 46, 3045-3059.
62. Carlson, H.A. and McCammon, J.A. (2000) Accommodating protein flexibility in computational drug design. Mol. Pharmacol. 57, 213-218.
63. Sine, S.M., Wang, H.L., and Gao, F. (2004) Toward atomic-scale understanding of ligand recognition in the muscle nicotinic receptor. Curr. Med. Chem. 11, 559-567.
64. Moran, O., Traverso, S., Elia, L., and Pusch, M. (2003) Molecular modeling of p-chlorophenoxyacetic acid binding to the CLC-0 channel. Biochemistry 42, 5176-5185.